Drug Type Peptibody, Biosimilar |
Synonyms Romiplostim Biosimilar (Sichuan Kelun Pharmaceutical Co., Ltd.), 罗米司亭生物类似药(四川科伦药业股份有限公司), A157 |
Target |
Action agonists |
Mechanism TPO receptor agonists(Thrombopoietin receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Thrombocytopenia | Phase 1 | China | 02 Jun 2020 | |
| Cardiovascular Diseases | Preclinical | United States | 01 Aug 2021 |






